Navigation Links
New screening approach uncovers potential alternative drug therapies for neuroblastoma
Date:5/23/2013

Nearly two-thirds of patients with high-risk neuroblastoma a common tumor that forms in the nerve cells of childrencannot be cured using tumor-killing cancer drugs. A study published by Cell Press in the May 23 issue of Chemistry & Biology reveals a new genomic approach to screen for compounds that could inhibit tumor growth by causing cancer cells to differentiate, or convert from immature cells to more specialized cell types. Using this screening method, the researchers identified a compound that causes neuroblastoma cells to differentiate, uncovering a promising new treatment strategy for this highly malignant pediatric cancer.

"New treatment approaches are very much needed for children with high-risk childhood cancers; that is, those that are metastatic at diagnosis and likely to recur," says senior study author Kimberly Stegmaier of the Dana-Farber/Children's Hospital Cancer Center and the Broad Institute of the Massachusetts Institute of Technology and Harvard University. "By focusing on an alternative strategy to treating neuroblastoma tumors, we identified a compound class that in early testing in neuroblastoma cells in the laboratory shows promise for treating children with this disease."

Beyond the standard approach of using drugs that kill tumor cells, another promising strategy is to identify compounds that promote differentiation, which causes tumor cells to stop dividing and growing. But the benefits of differentiation therapy had not been fully explored.

To address this need, Stegmaier and her team developed a method to screen small molecules for their ability to trigger differentiation in neuroblastoma cells. First, they treated these cells with drugs known to induce differentiation and looked for accompanying changes in the activity levels of genes. They found that 59 genes showed changes related to differentiation. Using this genetic signature for differentiation, they then screened nearly 2,000 small molecules and identified one compound that strongly promoted differentiation in neuroblastoma cells, especially when combined with a drug already approved to treat this type of cancer.

The newly identified compound works by selectively inhibiting a subset of gene-regulating proteins called histone deacetylases (HDACs). "This work supports the need to develop selective HDAC inhibitors for clinical application and, more broadly, illuminates the power of integrating signature-based screening with new approaches to chemical synthesis to provide novel biological insights into human disease," Stegmaier says.


'/>"/>

Contact: Mary Beth O'Leary
moleary@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Genetic screening could reveal hidden high risk for coronary heart disease
2. Pulse Oximetry Screening for Newborns a Reality in North Carolina
3. Bay Area Hospital Selects BESLER Consulting’s BVerified (SM)- Screening and Verification Solution
4. Memorial Hospital Wellness Vehicle to Offer Health Screenings at Affordable Assisted Living Community in St. Louis Metro East
5. Water’s Edge Dermatology Offers Complimentary Skin Cancer Screenings in May for Skin Cancer Awareness Month
6. Outsourced Ion Channel Primary Screening Trends & 2015 Forecast in New Market Research Report at ReportsnReports.com
7. PreCheck, Inc. Achieves Background Screening Credentialing Council Accreditation
8. PharmaSmart® and Kinney Drugs Partner up to Unveil Newest Advancement in Pharmacy-Based Biometric Screening and Mobile Interoperability
9. New Guidelines Suggest HIV Screening for All Adults
10. Personalizing prostate cancer screenings
11. Research finds targeted screening for hepatitis C is cost-effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... asked at a gathering of executive marketers this week about the value of ... , "Everything that has happened in business has brought us to the ...
(Date:9/20/2017)... ... September 20, 2017 , ... “They Sang At Her Funeral”: a tale of ... revealing the skeletons in their closets. “They Sang At Her Funeral” is the creation ... young and married with five children and twelve grandchildren. Before becoming a writer, Annalise ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, a leading ... Denise Flannery, to its strategic advisory and client development team. , In ... with clients across different industries to develop and implement market-justified strategies, modernize and ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... McFarland has joined its executive team as the President of its HealthBI ... care management systems and contact centers. , “Scott is a utility player ...
(Date:9/19/2017)... ... September 19, 2017 , ... MelaKids, a Laredo-based company, has ... filter. When we’re born, Nature gives us a full supply of melanin – ... we continuously lose this natural glare-reducing pigment; however, around the age of thirty, we ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... , Pa. and KALAMAZOO, Mich. , ... Allentown, Penn. , and OptiMed Specialty Pharmacy of ... business partnership to offer a strategic hub service that ... Healthcare,s highly sought-after personal spirometer, Spiro PD 2.0, and ... A spirometer is a medical device used to ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
(Date:9/7/2017)... , Sept. 7, 2017  For nearly two decades, New Life Agency ... Assisted Reproduction Insurance industry. Today, New Life Agency announces a powerful three-way ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
Breaking Medicine Technology: